Aclaris Therapeutics, Inc.ACRSEarnings & Financial Report
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on developing targeted therapies for immunological, inflammatory, and dermatological diseases. Its pipeline includes candidates for unmet needs like alopecia areata and vitiligo, serving global patient groups.
Revenue
$1.8M
Gross Profit
$1.3M
Operating Profit
$-18.4M
Net Profit
$-15.4M
Gross Margin
71.0%
Operating Margin
-1035.9%
Net Margin
-868.3%
YoY Growth
-35.8%
EPS
$-0.13
Aclaris Therapeutics, Inc. Q2 FY2025 Financial Summary
Aclaris Therapeutics, Inc. reported revenue of $1.8M (down 35.8% YoY) for Q2 FY2025, with a net profit of $-15.4M (down 40.4% YoY) (-868.3% margin). Cost of goods sold was $515.0K, operating expenses totaled $19.7M.
Key Financial Metrics
| Total Revenue | $1.8M |
|---|---|
| Net Profit | $-15.4M |
| Gross Margin | 71.0% |
| Operating Margin | -1035.9% |
| Report Period | Q2 FY2025 |
Aclaris Therapeutics, Inc. Annual Revenue by Year
Aclaris Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $7.8M).
| Year | Annual Revenue |
|---|---|
| 2025 | $7.8M |
| 2024 | $18.7M |
| 2023 | $31.2M |
| 2022 | $29.8M |
Aclaris Therapeutics, Inc. Quarterly Revenue & Net Profit History
Aclaris Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $1.3M | -85.9% | N/A | N/A |
| Q3 FY2025 | $3.3M | -24.1% | $-14.6M | -443.0% |
| Q2 FY2025 | $1.8M | -35.8% | $-15.4M | -868.3% |
| Q1 FY2025 | $1.5M | -39.3% | $-15.1M | -1036.8% |
| Q4 FY2024 | $9.2M | -47.6% | $-96.6M | -1048.3% |
| Q3 FY2024 | $4.3M | -53.2% | $-7.6M | -174.6% |
| Q2 FY2024 | $2.8M | +48.0% | $-11.0M | -397.2% |
| Q1 FY2024 | $2.4M | -5.1% | $-16.9M | -706.5% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.4M | $2.8M | $4.3M | $9.2M | $1.5M | $1.8M | $3.3M | $1.3M |
| YoY Growth | -5.1% | 48.0% | -53.2% | -47.6% | -39.3% | -35.8% | -24.1% | -85.9% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $174.1M | $161.1M | $182.4M | $220.3M | $198.1M | $189.1M | $175.5M | $160.5M |
| Liabilities | $32.1M | $27.2M | $52.2M | $64.8M | $54.0M | $57.4M | $55.4M | $57.4M |
| Equity | $142.0M | $133.8M | $130.2M | $155.6M | $144.1M | $131.7M | $120.1M | $103.1M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-20.8M | $-12.3M | $22.0M | $-8.9M | $-13.1M | $-10.0M | $-10.9M | $-47.1M |